Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 8/20 | 0.44 |
| ▸ | NOS2 | P35228 | 8/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7636658 | 0.98 | NOS1 (0.43) | NOS1NOS2CYP1A2EPHX1NOS3 | |
| SCHEMBL2106032 | 0.98 | NOS1 (0.43) | NOS1NOS2CYP1A2EPHX1NOS3 | |
| SCHEMBL1691768 | 0.94 | NOS1 (0.42) | NOS1NOS2CYP1A2EPHX1NOS3 | |
| SCHEMBL295542 | 0.94 | NOS1 (0.50) | NOS1NOS2CYP1A2NOS3 | |
| SCHEMBL10707537 | 0.92 | EPHX1 (0.41) | NOS1NOS2CYP1A2EPHX1NOS3 | |
| SCHEMBL7634559 | 0.92 | EPHX1 (0.41) | NOS1NOS2CYP1A2EPHX1NOS3 | |
| SCHEMBL5214635 | 0.92 | CYP1A2 (0.50) | NOS1NOS2CYP1A2NOS3ALDH1A1 | |
| SCHEMBL7300362 | 0.89 | SPHK2 (0.39) | NOS1NOS2CYP1A2EPHX1ALDH1A1 | |
| SCHEMBL6510677 | 0.87 | — | — | |
| SCHEMBL1219807 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140135361-A1 | ANTI-ALLERGY BENZOCYCLOHEPTATHIOPHENE DERIVATIVES | FUJIAN MINDONG REJUVENATION PHARMACEUTICAL CO., LTD. (CN) | 2014-05-15 | — | — | US | claimed |
| EP-2727919-A1 | BENZOCYCLOHEPTANETHIOPHENE DERIVATIVES FOR ANTI-ALLERGIC REACTIONS | Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd. (CN) | 2014-05-07 | — | — | EP | claimed |
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | claimed |
| WO-2005028474-A2 | PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | claimed |
| CN-1316419-A | Arenesulfonyl amino-iso hydroximic acid derivative | PFIZER (US) | 2001-10-10 | — | — | CN | claimed |
| CN-1304930-A | Arylsulfurylisooximino acid derivative | PFIZER (US) | 2001-07-25 | — | — | CN | claimed |
| CN-1305479-A | Pyrrolo [2,3-d] pyrmidine compounds | PFIZER PROD INC (US) | 2001-07-25 | — | — | CN | claimed |
| EP-2727919-B1 | BENZOCYCLOHEPTANETHIOPHENE DERIVATIVES FOR ANTI-ALLERGIC REACTIONS | FUJIAN MINDONG REJUVENATION PHARMACEUTICAL CO LTD (CN) | 2019-05-08 | — | — | EP | disclosed |
| US-10022362-B2 | Anti-allergy benzocycloheptathiophene derivatives | FUJIAN MINDONG REJUVENATION PHARMACEUTICAL CO., LTD (CN) | 2018-07-17 | — | — | US | disclosed |
| US-20160166563-A1 | Anti-Allergy Benzocycloheptathiophene Derivatives | FUJIAN MINDONG REJUVENATION PHARMACEUTICAL CO., LTD (CN) | 2016-06-16 | — | — | US | disclosed |
| EP-1542013-B1 | CHEMILUMINESCENCE ENHANCER | FUJIREBIO KK (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-9296731-B2 | Anti-allergy benzocycloheptathiophene derivatives | FUJIAN MINDONG REJUVENATION PHARMACEUTICAL CO., LTD. (CN) | 2016-03-29 | — | — | US | disclosed |
| US-8829030-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2014-09-09 | — | — | US | disclosed |
| CN-1316419-A | Arenesulfonyl amino-iso hydroximic acid derivative | PFIZER (US) | 2001-10-10 | — | — | CN | disclosed |
| CN-1305479-A | Pyrrolo [2,3-d] pyrmidine compounds | PFIZER PROD INC (US) | 2001-07-25 | — | — | CN | disclosed |
| CN-1304930-A | Arylsulfurylisooximino acid derivative | PFIZER (US) | 2001-07-25 | — | — | CN | disclosed |
| US-5679692-A | ANTIASTHMATIC, ANTIALLERGENS AND ANTIINFLAMMATORY AGENT | SCHERING CORPORATION (US) | 1997-10-21 | — | — | US | disclosed |
| US-5583000-A | DETECTING PRESENCE OF RETROVIRAL PROTEASES IN SAMPLE BY COMBINING WITH SPECIFIED COMPOUND AND DETECTING PRESENCE OF COMPLEXES FORMED | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-12-10 | — | — | US | disclosed |
| US-5583000-A | DETECTING PRESENCE OF RETROVIRAL PROTEASES IN SAMPLE BY COMBINING WITH SPECIFIED COMPOUND AND DETECTING PRESENCE OF COMPLEXES FORMED | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-12-10 | — | — | US | disclosed |
| US-4069196-A | Piperidyl esters of higher di-tri-, and polybasic aliphatic carboxylic acids as stabilizers for polymeric materials | CIBA-GEIGY CORPORATION (US) | 1978-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | NOS1 4622/4885NOS2 4854/4885CYP1A2 4825/4885 |
| US-20160166563-A1 | Anti-Allergy Benzocycloheptathiophene Derivatives | NR1H4, TST, CYP7A1 | NOS1 1809/4885NOS2 2362/4885CYP1A2 209/4885 |
| US-20140135361-A1 | ANTI-ALLERGY BENZOCYCLOHEPTATHIOPHENE DERIVATIVES | TST, HRH1, ABCB11 | NOS1 2387/4885NOS2 2713/4885CYP1A2 111/4885 |
| US-10022362-B2 | Anti-allergy benzocycloheptathiophene derivatives | NR1H4, TST, CYP7A1 | NOS1 1809/4885NOS2 2362/4885CYP1A2 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.